BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34629221)

  • 1. [Epidemiology of fibrosing interstitial lung diseases in the department of Haute Garonne].
    Villeneuve T; Prévot G; Lintz F; Mourin G; Ferry G; Bousquet E; Perelroizen H; Boghanim T; Faviez G; Noël-Savina E; Collot S; Le Borgne A; Didier A
    Rev Mal Respir; 2021 Dec; 38(10):972-979. PubMed ID: 34629221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
    Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
    Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
    [No Abstract]   [Full Text] [Related]  

  • 4. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
    Olson A; Hartmann N; Patnaik P; Wallace L; Schlenker-Herceg R; Nasser M; Richeldi L; Hoffmann-Vold AM; Cottin V
    Adv Ther; 2021 Feb; 38(2):854-867. PubMed ID: 33315170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.
    Olson AL; Gifford AH; Inase N; Fernández Pérez ER; Suda T
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural history of progressive fibrosing interstitial lung diseases.
    Kolb M; Vašáková M
    Respir Res; 2019 Mar; 20(1):57. PubMed ID: 30871560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 9. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
    Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.
    Duchemann B; Annesi-Maesano I; Jacobe de Naurois C; Sanyal S; Brillet PY; Brauner M; Kambouchner M; Huynh S; Naccache JM; Borie R; Piquet J; Mekinian A; Virally J; Uzunhan Y; Cadranel J; Crestani B; Fain O; Lhote F; Dhote R; Saidenberg-Kermanac'h N; Rosental PA; Valeyre D; Nunes H
    Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28775045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype.
    Inoue Y; Kaner RJ; Guiot J; Maher TM; Tomassetti S; Moiseev S; Kuwana M; Brown KK
    Chest; 2020 Aug; 158(2):646-659. PubMed ID: 32268131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries.
    Hilberg O; Hoffmann-Vold AM; Smith V; Bouros D; Kilpeläinen M; Guiot J; Morais A; Clemente S; Daniil Z; Papakosta D; Fretheim H; Neves S; Alfaro TM; Antoniou KM; Valveny N; Asijee G; Soulard S; Wuyts W
    ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35083316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
    Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.
    Takei R; Brown KK; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Suzuki A; Furukawa T; Fukuoka J; Johkoh T; Goto Y; Kondoh Y
    Respirology; 2022 May; 27(5):333-340. PubMed ID: 35293077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
    Li DY; Liu X; Huang JY; Hang WL; Yu GR; Xu Y
    Ther Adv Respir Dis; 2024; 18():17534666241232561. PubMed ID: 38414439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interstitial lung diseases among patients hospitalized in the Department of Respiratory Medicine in Radom District Hospital during the years 2000-2009].
    Szafrański W
    Pneumonol Alergol Pol; 2012; 80(6):523-32. PubMed ID: 23109204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Sarr C; Freiwald M
    BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse Pulmonary Ossification in Fibrosing Interstitial Lung Diseases: Prevalence and Associations.
    Egashira R; Jacob J; Kokosi MA; Brun AL; Rice A; Nicholson AG; Wells AU; Hansell DM
    Radiology; 2017 Jul; 284(1):255-263. PubMed ID: 28182861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.